{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:23:24Z","timestamp":1755221004906,"version":"3.43.0"},"reference-count":19,"publisher":"Scientific Scholar","content-domain":{"domain":["surgicalneurologyint.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background: <\/jats:title>\n<jats:p>A subependymal giant cell astrocytoma (SEGA) grows slowly near the foramen of Monro and develops in tuberous sclerosis complex patients. Large SEGA resection has a high risk of hemorrhage, resulting in irreversible sequelae. Mammalian target of rapamycin (mTOR) inhibitor has been approved for the treatment of SEGA which cannot be curatively treated surgically.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Case Description: <\/jats:title>\n<jats:p>An 8-year-old boy was found to have two nodules beside bilateral ventricles. After the interruption of regular examination, he was transported to the hospital with seizure, headache, and visual impairment caused by hydrocephalus. Computed tomography (CT) scan revealed two masses: one at each the left (60 \u00d7 50 \u00d7 60 mm) and right (20 \u00d7 10 \u00d7 10 mm) ventricles. An emergency ventricular outside shunt was placed, but reduction surgery could not be performed. Everolimus at 3 mg\/m<jats:sup>2<\/jats:sup> was orally administered as preoperative therapy. A reduction in tumor size was observed 2 months after everolimus initiation. Reduction surgery for the right-sided tumor was performed after discontinuation of the drug. The tumor at the left septum lucidum and caudate nucleus remained. Everolimus was administered again for residual tumor growth. After a series of surgeries, complete resection of both tumors was performed eventually.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Conclusion: <\/jats:title>\n<jats:p>This report shows preoperative treatment using mTOR inhibitor to be an effective strategy for unresectable large SEGA.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/sni_159_2025","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:59:48Z","timestamp":1754636388000},"page":"332","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful resection of large subependymal giant cell astrocytoma using presurgical mammalian target of rapamycin inhibitor"],"prefix":"10.25259","volume":"16","author":[{"given":"Mika","family":"Kawabe","sequence":"first","affiliation":[{"name":"Department of Pediatrics Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhisa","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medical Center, Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Ohue","sequence":"additional","affiliation":[{"name":"Department of Brain Stroke Center, Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"10.25259\/SNI_159_2025\/ref-1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2009.02567.x","article-title":"Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature","volume":"16","author":"Adriaensen","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pediatrneurol.2017.04.008","article-title":"Acute management of symptomatic subependymal giant cell astrocytoma with everolimus","volume":"72","author":"Arroyo","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-4632.2010.04727.x","article-title":"Tuberous sclerosis complex: Tumors and tumorigenesis","volume":"50","author":"Borkowska","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.25259\/SNI_159_2025\/ref-4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/jnen\/63.12.1236","article-title":"Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation","volume":"63","author":"Chan","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.25259\/SNI_159_2025\/ref-6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR inhibitors in tuberous sclerosis complex","volume":"10","author":"Curatolo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"10.25259\/SNI_159_2025\/ref-7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.25259\/SNI_159_2025\/ref-8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.25259\/SNI_159_2025\/ref-9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: A molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"10.25259\/SNI_159_2025\/ref-11","doi-asserted-by":"crossref","first-page":"1053.e1","DOI":"10.1016\/j.wneu.2017.08.122","article-title":"Presurgical administration of mtor inhibitors in patients with large subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"107","author":"Jiang","year":"2017","journal-title":"World Neurosurg"},{"key":"10.25259\/SNI_159_2025\/ref-12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.spen.2015.10.003","article-title":"Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex","volume":"22","author":"Jozwiak","year":"2015","journal-title":"Semin Pediatr Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.25259\/SNI_159_2025\/ref-14","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.25259\/SNI_159_2025\/ref-15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: Recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00701-014-2309-0","article-title":"Persistent communicating hydrocephalus in adult tuberous sclerosis patients: A possible therapeutic role for everolimus","volume":"157","author":"Laviv","year":"2015","journal-title":"Acta Neurochir (Wien)"},{"key":"10.25259\/SNI_159_2025\/ref-17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/jnnp.66.3.370","article-title":"Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis","volume":"66","author":"Nabbout","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.25259\/SNI_159_2025\/ref-18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpn.2011.09.006","article-title":"Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex","volume":"16","author":"Perek-Polnik","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.25259\/SNI_159_2025\/ref-19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the international tuberous sclerosis complex consensus conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"}],"container-title":["Surgical Neurology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/surgicalneurologyint.com\/successful-resection-of-large-subependymal-giant-cell-astrocytoma-using-presurgical-mammalian-target-of-rapamycin-inhibitor\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/successful-resection-of-large-subependymal-giant-cell-astrocytoma-using-presurgical-mammalian-target-of-rapamycin-inhibitor\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:59:51Z","timestamp":1754636391000},"score":1,"resource":{"primary":{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/successful-resection-of-large-subependymal-giant-cell-astrocytoma-using-presurgical-mammalian-target-of-rapamycin-inhibitor\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":19,"alternative-id":["10.25259\/SNI_159_2025"],"URL":"https:\/\/doi.org\/10.25259\/sni_159_2025","relation":{},"ISSN":["2152-7806","2229-5097"],"issn-type":[{"value":"2152-7806","type":"electronic"},{"value":"2229-5097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"332"}}